NO20045234L - 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer - Google Patents

2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer

Info

Publication number: NO20045234L
Authority: NO; Norway
Prior art keywords: vla; quinolinyl; processes; preparation; inhibitors
Prior art date: 2002-04-30

Application number

NO20045234A

Other languages

English (en)

Norwegian (no)

Inventor

Marie-Agnes Lassoie

Sylvain Routier

Luc Quere

Laurent Knerr

Thierry Demaude

Francoise De Laveleye-Defais

Thierry Kogej

Gerald Guillaumet

Original Assignee

Ucb Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-30

Filing date

2004-11-29

Publication date

2005-01-18

2004-11-29 Application filed by Ucb Sa filed Critical Ucb Sa

2005-01-18 Publication of NO20045234L publication Critical patent/NO20045234L/no

Links

108010008212 Integrin alpha4beta1 Proteins 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
201000004624 Dermatitis Diseases 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010010741 Conjunctivitis Diseases 0.000 abstract 1
208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
208000003251 Pruritus Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
208000024780 Urticaria Diseases 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
235000020932 food allergy Nutrition 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
201000009890 sinusitis Diseases 0.000 abstract 1
208000017520 skin disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)

NO20045234A 2002-04-30 2004-11-29 2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer NO20045234L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02009746		2002-04-30
PCT/EP2003/003909 WO2003093237A1 (en)	2002-04-30	2003-04-15	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors

Publications (1)

Publication Number	Publication Date
NO20045234L true NO20045234L (no)	2005-01-18

Family

ID=29286106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20045234A NO20045234L (no)	2002-04-30	2004-11-29	2,6-kinolinyl- og 2,6-naftylderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som VLA-4-inhibitorer

Country Status (24)

Country	Link
US (2)	US7638630B2 (pl)
EP (2)	EP1501801B1 (pl)
JP (1)	JP2005535583A (pl)
KR (1)	KR100841165B1 (pl)
CN (2)	CN1649842A (pl)
AR (1)	AR039341A1 (pl)
AT (1)	ATE384699T1 (pl)
AU (1)	AU2003232472B2 (pl)
BR (1)	BR0309719A (pl)
CA (1)	CA2484954C (pl)
CO (1)	CO5450243A1 (pl)
CU (1)	CU23415B7 (pl)
DE (1)	DE60318839T2 (pl)
ES (1)	ES2298543T3 (pl)
IL (1)	IL164516A0 (pl)
MX (1)	MXPA04010673A (pl)
MY (1)	MY135218A (pl)
NO (1)	NO20045234L (pl)
NZ (1)	NZ536180A (pl)
PL (1)	PL373763A1 (pl)
RU (1)	RU2315041C2 (pl)
TW (2)	TWI267508B (pl)
WO (1)	WO2003093237A1 (pl)
ZA (1)	ZA200408447B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003093237A1 (en) *	2002-04-30	2003-11-13	Ucb, S.A.	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
US7153889B2 (en)	2002-11-12	2006-12-26	Abbott Laboratories	Bicyclic-substituted amines as histamine-3 receptor ligands
EP1595870B1 (en) *	2003-02-20	2015-09-23	Ajinomoto Co., Inc.	Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
US7098222B2 (en)	2004-05-12	2006-08-29	Abbott Laboratories	Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7145005B2 (en)	2004-05-12	2006-12-05	Abbott Laboratories	2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
US7205316B2 (en)	2004-05-12	2007-04-17	Abbott Laboratories	Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
CA2610800A1 (en)	2005-06-09	2006-12-14	Ucb Pharma, S.A.	2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
KR20090086539A (ko)	2006-11-14	2009-08-13	산텐 세이야꾸 가부시키가이샤	(치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
WO2008125215A1 (en) *	2007-04-12	2008-10-23	Ucb Pharma, S.A.	Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008125210A1 (en) *	2007-04-12	2008-10-23	Ucb Pharma, S.A.	Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008138592A1 (en) *	2007-05-14	2008-11-20	Ucb Pharma, S.A.	Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) *	2007-05-16	2008-11-20	Ucb Pharma, S.A.	Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
US7902181B2 (en) *	2007-12-12	2011-03-08	Astrazeneca Ab	Compounds 010
EP2085407A1 (en)	2008-02-04	2009-08-05	Sahltech I Göteborg AB	Treatment of idiopathic thrombocytopenic purpura
TWI510240B (zh) *	2008-05-12	2015-12-01		由具有取代氧基之２，２，４－三甲基－６－苯基－１，２－二氫喹啉衍生物組成之糖皮質激素受體激動劑
EP2467159A1 (en)	2009-08-20	2012-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20150368213A1 (en) *	2014-06-20	2015-12-24	The University of Montana, Missoula, MT	Novel Inhibitors of System Xc-
MX385777B (es) *	2014-12-24	2025-03-04	Lg Chemical Ltd	Derivado de biarilo como agonista de gpr120.
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
DK3873884T3 (da)	2018-10-30	2025-02-17	Gilead Sciences Inc	3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
ES2987796T3 (es)	2018-10-30	2024-11-18	Gilead Sciences Inc	Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092394A1 (en)	2018-10-30	2020-05-07	Gilead Sciences, Inc.	Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en)	2018-10-30	2020-05-07	Gilead Sciences, Inc.	COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2020329207B2 (en)	2019-08-14	2024-02-29	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin
JP7635962B2 (ja) *	2021-01-12	2025-02-26	国立大学法人山口大学	フルオロアルキル置換ビニルフルオロアルカンスルホニルアミドの製造方法
US20240301512A1 (en)	2021-01-29	2024-09-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
CN116410136B (zh) *	2023-03-03	2025-07-11	五邑大学	一种喹啉衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2909214B2 (ja) *	1992-08-19	1999-06-23	フアイザー・インコーポレイテツド	置換ベンジルアミノ窒素含有非芳香族複素環化合物
US5550139A (en) *	1994-01-03	1996-08-27	The Wichita State University	Serine protease inhibitors
JP2920741B2 (ja) *	1994-12-14	1999-07-19	参天製薬株式会社	新規１，３−ジアルキルウレア誘導体
WO1996018606A1 (en) *	1994-12-14	1996-06-20	Santen Pharmaceutical Co., Ltd.	Novel 1,3-dialkylurea derivatives
JPH0987291A (ja) *	1995-09-26	1997-03-31	Wakamoto Pharmaceut Co Ltd	新規なアラニン誘導体
AU8191998A (en)	1997-02-04	1998-08-25	Trega Biosciences, Inc.	4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
AR016133A1 (es) *	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
KR100554815B1 (ko) *	1997-08-22	2006-02-22	에프. 호프만-라 로슈 아게	엔-아로일페닐알라닌 유도체
PT1114028E (pt) *	1998-08-26	2007-02-28	Aventis Pharma Ltd	Aza-biciclos moduladores da inibição da adesão celular
EP1175412A1 (en) *	1999-04-28	2002-01-30	Dr. Reddy's Research Foundation	Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
US6280442B1 (en) *	1999-09-01	2001-08-28	Sdgi Holdings, Inc.	Multi-axial bone screw assembly
US6399599B1 (en) *	1999-10-13	2002-06-04	Novartis Ag	Substituted 2-oxo-1,4-diazacycloalkanes
WO2003093237A1 (en) *	2002-04-30	2003-11-13	Ucb, S.A.	2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
CA2610800A1 (en)	2005-06-09	2006-12-14	Ucb Pharma, S.A.	2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

2003
- 2003-04-15 WO PCT/EP2003/003909 patent/WO2003093237A1/en not_active Ceased
- 2003-04-15 RU RU2004135304/04A patent/RU2315041C2/ru not_active IP Right Cessation
- 2003-04-15 BR BR0309719-6A patent/BR0309719A/pt not_active IP Right Cessation
- 2003-04-15 CA CA2484954A patent/CA2484954C/en not_active Expired - Fee Related
- 2003-04-15 KR KR1020047017498A patent/KR100841165B1/ko not_active Expired - Fee Related
- 2003-04-15 US US10/513,347 patent/US7638630B2/en not_active Expired - Fee Related
- 2003-04-15 MX MXPA04010673A patent/MXPA04010673A/es active IP Right Grant
- 2003-04-15 JP JP2004501376A patent/JP2005535583A/ja not_active Ceased
- 2003-04-15 CN CNA038097907A patent/CN1649842A/zh active Pending
- 2003-04-15 CN CNA2007101934884A patent/CN101200450A/zh active Pending
- 2003-04-15 ES ES03747411T patent/ES2298543T3/es not_active Expired - Lifetime
- 2003-04-15 EP EP03747411A patent/EP1501801B1/en not_active Expired - Lifetime
- 2003-04-15 NZ NZ536180A patent/NZ536180A/en not_active IP Right Cessation
- 2003-04-15 PL PL03373763A patent/PL373763A1/pl not_active Application Discontinuation
- 2003-04-15 AU AU2003232472A patent/AU2003232472B2/en not_active Ceased
- 2003-04-15 EP EP07017712A patent/EP1870402A1/en not_active Withdrawn
- 2003-04-15 AT AT03747411T patent/ATE384699T1/de not_active IP Right Cessation
- 2003-04-15 DE DE60318839T patent/DE60318839T2/de not_active Expired - Lifetime
- 2003-04-23 AR ARP030101389A patent/AR039341A1/es unknown
- 2003-04-25 TW TW092109709A patent/TWI267508B/zh not_active IP Right Cessation
- 2003-04-25 TW TW094147669A patent/TWI268278B/zh active
- 2003-04-29 CO CO03035403A patent/CO5450243A1/es not_active Application Discontinuation
- 2003-04-29 MY MYPI20031612A patent/MY135218A/en unknown
2004
- 2004-10-12 IL IL16451604A patent/IL164516A0/xx unknown
- 2004-10-19 ZA ZA200408447A patent/ZA200408447B/en unknown
- 2004-11-01 CU CU20040252A patent/CU23415B7/es not_active IP Right Cessation
- 2004-11-29 NO NO20045234A patent/NO20045234L/no unknown
2009
- 2009-10-23 US US12/604,959 patent/US20100105681A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1870402A1 (en)	2007-12-26
EP1501801B1 (en)	2008-01-23
TWI267508B (en)	2006-12-01
IL164516A0 (en)	2005-12-18
CO5450243A1 (es)	2004-10-29
CA2484954C (en)	2010-02-09
US20080064720A1 (en)	2008-03-13
EP1501801A1 (en)	2005-02-02
PL373763A1 (pl)	2005-09-19
DE60318839T2 (de)	2009-01-22
MY135218A (en)	2008-02-29
TW200616960A (en)	2006-06-01
AR039341A1 (es)	2005-02-16
NZ536180A (en)	2005-04-29
CA2484954A1 (en)	2003-11-13
KR100841165B1 (ko)	2008-06-24
DE60318839D1 (de)	2008-03-13
TWI268278B (en)	2006-12-11
RU2004135304A (ru)	2005-07-10
AU2003232472A1 (en)	2003-11-17
CU23415B7 (es)	2009-09-08
TW200404061A (en)	2004-03-16
CN1649842A (zh)	2005-08-03
ZA200408447B (en)	2006-07-26
JP2005535583A (ja)	2005-11-24
KR20040106425A (ko)	2004-12-17
ES2298543T3 (es)	2008-05-16
ATE384699T1 (de)	2008-02-15
BR0309719A (pt)	2005-02-09
WO2003093237A1 (en)	2003-11-13
RU2315041C2 (ru)	2008-01-20
MXPA04010673A (es)	2005-09-30
CN101200450A (zh)	2008-06-18
US7638630B2 (en)	2009-12-29
US20100105681A1 (en)	2010-04-29
AU2003232472B2 (en)	2008-09-18

Publication	Publication Date	Title
BR0309719A (pt)	2005-02-09	Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, uso do composto, e, intermediários de sìntese
ECSP067057A (es)	2007-03-29	Nuevos derivados de piridazin-3(2h)-ona
NO20080125L (no)	2008-01-08	2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament
SG155909A1 (en)	2009-10-29	Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
FI935379A0 (fi)	1993-12-01	Katekoldietrar som fungerar som selektiva PDEIV-inhibitorer
BR0010607A (pt)	2002-02-13	Derivados de piperidina úteis como antagonistas de ccr5
NO20084005L (no)	2008-09-19	Aminderivater
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20063928L (no)	2006-10-31	Substituerte kinolinforbindelser
TW200505862A (en)	2005-02-16	2-amino-pyridine derivatives useful for the treatment of diseases
NO20083500L (no)	2008-09-02	1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
NO20070994L (no)	2007-04-26	N-hydroksamid derivater og anvendelse derav
HRP20050119A2 (en)	2006-05-31	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
CY1111327T1 (el)	2015-08-05	Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
NO20076682L (no)	2008-03-05	Nye pyridinanaloger
TW200505865A (en)	2005-02-16	Compounds useful for the treatment of diseases
BRPI0508927A (pt)	2007-08-14	compostos úteis para o tratamento de doenças
CN106831577A (zh)	2017-06-13	一种c3取代的四氢异喹啉衍生物及其制备方法和应用
UA90319C2 (ru)	2010-04-26	Соединения 2,6-хинолинила и их применение как лекарственного средства
TW200745087A (en)	2007-12-16	CCR5 antagonists useful for treating HIV
FI963882A0 (fi)	1996-09-27	Bentsotiatsolijohdannaiset 5-lipoksigenaasibiosynteesin estoaineina
HUP0302121A2 (hu)	2003-10-28	{[(Biciklil- vagy heterobiciklil-metil)-szulfonil]-alkil}-csoporttal szubsztituált N-hidroxi-formamidok, eljárás előállításukra, intermedierek és a vegyületeket tartalmazó gyógyszerkészítmények
NO20064114L (no)	2006-12-08	Fremgangsmate for fremstilling av N-arylpiperazinderivater
PT1406865E (pt)	2006-06-30	Derivados de acido succinico
JPS6039262B2 (ja)	1985-09-05	第３級ブチルフェノ−ル誘導体